Elicio Therapeutics, Inc. (ELTX) Stock Profile — Insider Trades & Financials

Net Income-$7.7M

EPS$-2.09

Market Cap$186.1M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Robert Connelly

CEO & Executive Director

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Founded: 2011
Employees: 32
Headquarters

⚡

Core Efficiency

ROE?

-471.76%

ROA?

-29.84%

D/E Ratio?

14.81

📊

Profitability Ratios

Current Ratio?

2.38

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 1, 2026 (in 145 days)

Annual Report (10-K) — Based on filing pattern

Sep 1, 2026

Predicted10-K

Mar 12, 2026

10-KQ4 20252d after period end

Mar 12, 2026

10-KFY 202571d after period end

Nov 13, 2025

10-QQ3 20253d after period end

Aug 7, 2025

10-QQ2 20252d after period end

May 13, 2025

10-QQ1 20254d after period end

Mar 31, 2025

10-KQ4 20246d after period end

Mar 31, 2025

10-KFY 202590d after period end

Nov 13, 2024

10-QQ3 20245d after period end

Loading company sections...

Elicio Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness